43.03
前日終値:
$42.98
開ける:
$42.65
24時間の取引高:
2.32M
Relative Volume:
1.31
時価総額:
$6.85B
収益:
$705.14M
当期純損益:
$-453.90M
株価収益率:
-14.15
EPS:
-3.04
ネットキャッシュフロー:
$-551.29M
1週間 パフォーマンス:
+1.86%
1か月 パフォーマンス:
+7.74%
6か月 パフォーマンス:
+34.89%
1年 パフォーマンス:
-16.15%
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
名前
Ionis Pharmaceuticals Inc
セクター
電話
(760) 931-9200
住所
2855 GAZELLE COURT, CARLSBAD, CA
IONS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
IONS
Ionis Pharmaceuticals Inc
|
43.03 | 6.85B | 705.14M | -453.90M | -551.29M | -3.04 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-07-01 | アップグレード | Barclays | Equal Weight → Overweight |
2025-04-07 | 開始されました | H.C. Wainwright | Buy |
2025-03-31 | 開始されました | Redburn Atlantic | Neutral |
2024-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2024-07-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-07-16 | 再開されました | Jefferies | Buy |
2024-06-14 | アップグレード | Bernstein | Underperform → Mkt Perform |
2024-04-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2024-01-02 | アップグレード | BofA Securities | Neutral → Buy |
2023-10-23 | アップグレード | BofA Securities | Underperform → Neutral |
2023-09-29 | 開始されました | Raymond James | Strong Buy |
2023-07-31 | アップグレード | Citigroup | Neutral → Buy |
2023-06-07 | 再開されました | Piper Sandler | Overweight |
2023-05-04 | アップグレード | Citigroup | Sell → Neutral |
2023-03-21 | 開始されました | Bernstein | Underperform |
2022-12-21 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2022-09-09 | 再開されました | Morgan Stanley | Overweight |
2022-07-18 | 再開されました | Oppenheimer | Outperform |
2022-03-31 | 再開されました | Piper Sandler | Overweight |
2022-03-01 | 開始されました | Citigroup | Sell |
2022-03-01 | 開始されました | Guggenheim | Buy |
2022-02-01 | ダウングレード | BofA Securities | Buy → Underperform |
2021-12-14 | アップグレード | William Blair | Mkt Perform → Outperform |
2021-05-07 | アップグレード | UBS | Sell → Neutral |
2021-03-01 | アップグレード | Barclays | Underweight → Equal Weight |
2020-12-16 | 開始されました | UBS | Sell |
2020-12-15 | アップグレード | Cowen | Market Perform → Outperform |
2020-09-14 | 再開されました | JP Morgan | Neutral |
2020-09-02 | 開始されました | The Benchmark Company | Hold |
2020-06-01 | 再開されました | Oppenheimer | Outperform |
2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
2020-03-05 | 開始されました | Citigroup | Buy |
2019-12-13 | 開始されました | Oppenheimer | Outperform |
2019-11-13 | 開始されました | BofA/Merrill | Buy |
2019-11-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
2019-09-10 | アップグレード | Bernstein | Mkt Perform → Outperform |
2018-08-08 | 繰り返されました | Stifel | Hold |
2018-08-07 | 繰り返されました | Stifel | Hold |
2018-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
2017-10-06 | 再開されました | Goldman | Sell |
2017-08-17 | 開始されました | Evercore ISI | Outperform |
2017-08-09 | 繰り返されました | Stifel | Hold |
2017-03-10 | ダウングレード | Goldman | Neutral → Sell |
2016-12-28 | 繰り返されました | BMO Capital Markets | Outperform |
2016-12-27 | 繰り返されました | Leerink Partners | Mkt Perform |
すべてを表示
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) - simplywall.st
How does Ionis Pharmaceuticals Inc. generate profit in a changing economyAI Powered Target Finder For Consistent Profits - jammulinksnews.com
Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
How volatile is Ionis Pharmaceuticals Inc. stock compared to the marketPre Market Trend Scanner With High Returns - jammulinksnews.com
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook - MSN
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2025 Earnings Call Transcript - Insider Monkey
Ionis Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Ionis Pharmaceuticals Reports Strong Earnings and Growth - TipRanks
Morgan Stanley Upgrades Ionis Pharmaceuticals (IONS) - MSN
Ionis raises 2025 revenue guidance to $850M with Tryngolza momentum and Donidalorsen launch on track - MSN
How does Ionis Pharmaceuticals Inc. compare to its industry peersAI Powered Tips With High Returns - jammulinksnews.com
Ionis (IONS) Q2 Revenue Soars 101% - The Globe and Mail
Raymond James Raises Ionis Pharmaceuticals (IONS) Price Target t - GuruFocus
UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach - insights.citeline.com
Ionis Pharmaceuticals stock price target raised to $65 from $50 at H.C. Wainwright - Investing.com Canada
Ionis reports second quarter 2025 financial results and highlights progress on key programs - BioSpace
Ionis Pharmaceuticals Inc (IONS) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
Ionis Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Morgan Stanley upgrades Ionis Pharmaceuticals stock rating on strong Tryngolza launch - Investing.com India
Ionis Pharmaceuticals' 2025 Q2 Earnings: A Launch-Driven Growth Story with Multi-Billion-Dollar Potential - AInvest
Ionis Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:IONS) - Seeking Alpha
Earnings call transcript: Ionis Pharmaceuticals Q2 2025 Surpasses Revenue Expectations - Investing.com Australia
Ionis (IONS) Q2 2025 Earnings Call Transcript - AOL.com
Why Ionis Pharmaceuticals Shares Are Up After Q2 ReportIonis Pharmaceuticals (NASDAQ:IONS) - Benzinga
Ionis Q2 2025 slides: TRYNGOLZA sales surge as pipeline advances By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Reports Strong Q2 2025 Financial Results - TradingView
Ionis Pharmaceuticals' Q2 Outperformance and Strategic Pipeline Catalysts: A High-Conviction Buy Before Earnings Release? - AInvest
Ionis Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings - Yahoo Finance
Ionis Pharmaceuticals: Q2 Earnings Snapshot - The Washington Post
Ionis Pharmaceuticals Inc. May Be Forming Higher Low — Chartwatchers AlertStock Market Entry Timing Signals Revealed - metal.it
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Too Much Debt? - simplywall.st
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Janux Therapeutics Inc (JANX) - The Globe and Mail
Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency - Insider Monkey
What is the dividend policy of Ionis Pharmaceuticals Inc. stockTop Growth Entry Points To Watch Now - jammulinksnews.com
What makes Ionis Pharmaceuticals Inc. stock price move sharplyDiscover stocks with superior performance - jammulinksnews.com
Has Ionis Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility Review Free Weekly Return Pick Forecast Reports - metal.it
Is it the right time to buy Ionis Pharmaceuticals Inc. stockOutstanding trading profits - jammulinksnews.com
Ionis Pharmaceuticals IONS 2025Q2 Earnings Preview Upside Potential on Revenue Growth - AInvest
Why is Ionis Pharmaceuticals Inc. stock attracting strong analyst attentionGet timely alerts on market opportunities - jammulinksnews.com
What is the risk reward ratio of investing in Ionis Pharmaceuticals Inc. stockAchieve consistent double-digit returns - jammulinksnews.com
What are analysts’ price targets for Ionis Pharmaceuticals Inc. in the next 12 monthsStay ahead with daily expert stock picks - jammulinksnews.com
Does Ionis Pharmaceuticals Inc. stock perform well during market downturnsSuperior return velocity - jammulinksnews.com
What institutional investors are buying Ionis Pharmaceuticals Inc. stockInvest in stocks with strong fundamentals - jammulinksnews.com
When is Ionis Pharmaceuticals Inc. stock expected to show significant growthConsistently outstanding ROI - jammulinksnews.com
Ionis Pharmaceuticals Announces Positive Donidalorsen Results for Hereditary Angioedema Published in JACI In Practice - MSN
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly? - 富途牛牛
Ionis Pharmaceuticals Gains CHMP Approval for Tryngolza: Analysts Project 36.63% Upside - AInvest
Ionis Pharmaceuticals Inc. Stock Analysis and ForecastFree Stock Market Real-Time Monitoring - PrintWeekIndia
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
Ionis Pharmaceuticals Inc (IONS) 財務データ
収益
当期純利益
現金流量
EPS
Ionis Pharmaceuticals Inc (IONS) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
LOSCALZO JOSEPH | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
36,330 |
YANG MICHAEL J. | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
6,010 |
WENDER JOSEPH H | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
136,835 |
PARSHALL B LYNNE | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
91,344 |
HERMAN JOAN E | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
46,086 |
Hayden Michael R | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
54,298 |
Diaz Allene M. | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
19,795 |
BERTHELSEN SPENCER R | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
156,013 |
Monia Brett P | Chief Executive Officer |
Jul 11 '25 |
Sale |
41.74 |
1,160 |
48,416 |
179,820 |
Hayden Michael R | Director |
May 01 '25 |
Buy |
31.86 |
15,000 |
477,900 |
50,219 |
大文字化:
|
ボリューム (24 時間):